Abstract 1130: Leveraging the IVIS imaging technologies for drug potency testing in orthotopic and metastatic tumor models

Abstract Assessing anti-tumor drug potency is significantly enhanced using orthotopic and metastasis mouse tumor models. These models imitate the tumor's native environment, biological complexities, and challenges of drug delivery via blood perfusion, thereby providing a high predictive value for clinical outcomes. In this poster, we demonstrate how the IVIS optical imaging technology is employed to determine the effects of two drugs on two tumor models: •The KRAS (G12C) inhibitor, AMG510, was evaluated on the luciferase-expressing Miapaca-2 pancreatic orthotopic model •The third-generation EGFR inhibitor, AZD9291, was tested on the luciferase-expressing NIC-H1975 intracranial metastatic model Both drugs showed significant anti-tumor activity. In addition to potency testing, each drug was administered in single doses for pharmacodynamic analysis, evaluating pERK/ERK and DUSP6 levels. The pERK levels decreased after treatment, which is in line with the mechanism of action of the inhibitors. Our research illustrates that IVIS imaging offers a robust method for monitoring anti-tumor activity of drugs in orthotopic and metastatic tumor models, empowering scientists to assess new drug candidates by using biologically relevant animal models. Citation Format: Jingqi Huang, Jing Jin, Hongchen Duan, Xueqin Yang, Wenhao Jin, Yiming Zhang, Lihui Zhang, Gaoyang Xu, Liya Xie, Wentao Li. Leveraging the IVIS imaging technologies for drug potency testing in orthotopic and metastatic tumor models abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts) ; 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84 (6Suppl): Abstract nr 1130.